Oxidative stress represents a fundamental pathological process in neurodegenerative diseases characterized by an imbalance between reactive oxygen species (ROS) production and cellular antioxidant defense mechanisms. This investment landscape analyzes therapeutic approaches targeting oxidative stress mechanisms in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and related disorders. The brain's high metabolic rate, lipid content, and relatively limited antioxidant capacity make it particularly vulnerable to oxidative damage.
The brain employs multiple enzymatic systems to combat oxidative stress:
Mitochondrial dysfunction is a primary source of ROS in neurodegenerative diseases:
The NRF2 (Nuclear factor erythroid 2-related factor 2) pathway is the master regulator of antioxidant response:
As of 2026, therapeutic candidates targeting oxidative stress mechanisms have progressed through various clinical stages:
| Stage | Mechanism | Candidates | Primary Indications |
|---|---|---|---|
| Phase 3 | Nrf2 activators | 2 | AD, COPD |
| Phase 2 | Mitochondrial antioxidants | 8 | PD, AD, ALS |
| Phase 2 | NAD+ precursors | 6 | AD, PD |
| Phase 1 | SOD mimics | 4 | ALS, AD |
| Phase 1 | Glutathione enhancers | 5 | PD, AD |
| Pre-clinical | Peroxiredoxin activators | 15+ | Neurodegeneration |
The Nrf2 pathway represents a promising therapeutic target for enhancing endogenous antioxidant defenses[1].
Sulforaphane — Found in cruciferous vegetables, activates Nrf2 through Keap1 modification. Currently in multiple clinical trials for neurodegenerative indications[2].
Dimethyl fumarate (Tecfidera) — FDA-approved for multiple sclerosis, activates Nrf2 pathway
Mitochondrial-targeted antioxidants aim to scavenge ROS at their site of production[3].
MitoQ (mitoquinone mesylate) — CoQ10 conjugated to triphenylphosphonium cation for mitochondrial targeting
CoQ10 (Ubiquinone/Ubiquinol) — Electron carrier and antioxidant
Idebenone — Synthetic CoQ10 analog with enhanced bioavailability
NAD+ depletion contributes to oxidative stress through impaired sirtuin activity and mitochondrial function[4].
Nicotinamide riboside (NR) — NAD+ precursor in clinical development
Nicotinamide mononucleotide (NMN) — Direct NAD+ precursor
Synthetic superoxide dismutase mimics offer potential for scavenging superoxide radicals[5].
EPI-743 (Vatiquinone) — Para-benzoquinone derivative
MnTnBuOE-2-PyP5+ (BMX-010) — Mn porphyrin SOD mimic
Glutathione is the most abundant intracellular antioxidant.
N-acetylcysteine (NAC) — Glutathione precursor
Sulforaphane (also in Nrf2 activators) — Upregulates glutathione synthesis
Alpha-lipoic acid — Regenerates glutathione and other antioxidants
Peroxiredoxins are highly conserved thiol-dependent peroxidases[6].
| Company | Pipeline Focus | Key Compounds |
|---|---|---|
| Biogen | Nrf2 activators | Dimethyl fumarate |
| AbbVie | Mitochondrial health | ABBV-954 |
| Novartis | NAD+ boosters | NIAGEN partnerships |
| Roche | Antioxidant approaches | RG7835 |
| BMS | Glutathione modulators | Various pre-clinical |
| Company | Focus Area | Stage |
|---|---|---|
| MitoQ Limited | MitoQ | Phase 2/3 |
| ChromaDex | NR (Niagen) | Phase 2 |
| BioElectron Technology | EPI-743 | Phase 2/3 |
| Restorbio | NAD+ precursors | Phase 1 |
| CytoPedia | SOD mimics | Pre-clinical |
Oxidative stress represents a promising therapeutic target with multiple compounds in various stages of development. The most advanced programs include Nrf2 activators, mitochondrial antioxidants (particularly CoQ10 and MitoQ), and NAD+ precursors. Key challenges include blood-brain barrier penetration and validation of target engagement biomarkers. The field continues to evolve with increasing understanding of redox biology and mitochondrial dynamics in neurodegeneration.
Sandberg M, et al. Nrf2-regulated cellular adaptation to oxidative stress in neurodegenerative diseases. Free Radic Biol Med. 2014. ↩︎
Russo M, et al. Sulforaphane induces Nrf2-dependent antioxidant response in human neuroblastoma cells. Neurochem Res. 2014. ↩︎
Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009. ↩︎
Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014. ↩︎
Batinic-Haberle I, et al. SOD mimics and their potential therapeutic applications. Antioxid Redox Signal. 2009. ↩︎
Rhee SG, et al. Peroxiredoxins: A historical overview and speculative preview. Free Radic Biol Med. 2007. ↩︎